124 related articles for article (PubMed ID: 16646038)
1. Functional characterization of a soluble gp130 isoform and its therapeutic capacity in an experimental model of inflammatory arthritis.
Richards PJ; Nowell MA; Horiuchi S; McLoughlin RM; Fielding CA; Grau S; Yamamoto N; Ehrmann M; Rose-John S; Williams AS; Topley N; Jones SA
Arthritis Rheum; 2006 May; 54(5):1662-72. PubMed ID: 16646038
[TBL] [Abstract][Full Text] [Related]
2. Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer.
Rose-John S; Scheller J; Elson G; Jones SA
J Leukoc Biol; 2006 Aug; 80(2):227-36. PubMed ID: 16707558
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of interleukin-6-transsignaling via gp130-Fc in hemorrhagic shock and sepsis.
Mees ST; Toellner S; Marx K; Faendrich F; Kallen KJ; Schroeder J; Haier J; Kahlke V
J Surg Res; 2009 Dec; 157(2):235-42. PubMed ID: 19589542
[TBL] [Abstract][Full Text] [Related]
4. Local blockade of IL-6R signaling induces lung CD4+ T cell apoptosis in a murine model of asthma via regulatory T cells.
Finotto S; Eigenbrod T; Karwot R; Boross I; Doganci A; Ito H; Nishimoto N; Yoshizaki K; Kishimoto T; Rose-John S; Galle PR; Neurath MF
Int Immunol; 2007 Jun; 19(6):685-93. PubMed ID: 17496315
[TBL] [Abstract][Full Text] [Related]
5. Regulation of pre-B cell colony-enhancing factor by STAT-3-dependent interleukin-6 trans-signaling: implications in the pathogenesis of rheumatoid arthritis.
Nowell MA; Richards PJ; Fielding CA; Ognjanovic S; Topley N; Williams AS; Bryant-Greenwood G; Jones SA
Arthritis Rheum; 2006 Jul; 54(7):2084-95. PubMed ID: 16802343
[TBL] [Abstract][Full Text] [Related]
6. No inhibition of IL-27 signaling by soluble gp130.
Scheller J; Schuster B; Hölscher C; Yoshimoto T; Rose-John S
Biochem Biophys Res Commun; 2005 Jan; 326(4):724-8. PubMed ID: 15607729
[TBL] [Abstract][Full Text] [Related]
7. Interleukin-6 signalling in juvenile idiopathic arthritis is limited by proteolytically cleaved soluble interleukin-6 receptor.
Peake NJ; Khawaja K; Myers A; Nowell MA; Jones SA; Rowan AD; Cawston TE; Foster HE
Rheumatology (Oxford); 2006 Dec; 45(12):1485-9. PubMed ID: 16690760
[TBL] [Abstract][Full Text] [Related]
8. The soluble Interleukin 6 receptor: generation and role in inflammation and cancer.
Chalaris A; Garbers C; Rabe B; Rose-John S; Scheller J
Eur J Cell Biol; 2011; 90(6-7):484-94. PubMed ID: 21145125
[TBL] [Abstract][Full Text] [Related]
9. Autoimmune arthritis associated with mutated interleukin (IL)-6 receptor gp130 is driven by STAT3/IL-7-dependent homeostatic proliferation of CD4+ T cells.
Sawa S; Kamimura D; Jin GH; Morikawa H; Kamon H; Nishihara M; Ishihara K; Murakami M; Hirano T
J Exp Med; 2006 Jun; 203(6):1459-70. PubMed ID: 16717113
[TBL] [Abstract][Full Text] [Related]
10. Interleukin-6 trans-signalling in chronic inflammation and cancer.
Scheller J; Ohnesorge N; Rose-John S
Scand J Immunol; 2006 May; 63(5):321-9. PubMed ID: 16640655
[TBL] [Abstract][Full Text] [Related]
11. Functional expression of a biologically active fragment of soluble gp130 as an ELP-fusion protein in transgenic plants: purification via inverse transition cycling.
Lin M; Rose-John S; Grötzinger J; Conrad U; Scheller J
Biochem J; 2006 Sep; 398(3):577-83. PubMed ID: 16716147
[TBL] [Abstract][Full Text] [Related]
12. Cloning of novel soluble gp130 and detection of its neutralizing autoantibodies in rheumatoid arthritis.
Tanaka M; Kishimura M; Ozaki S; Osakada F; Hashimoto H; Okubo M; Murakami M; Nakao K
J Clin Invest; 2000 Jul; 106(1):137-44. PubMed ID: 10880057
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic strategies for targeting the IL-6/STAT3 cytokine signaling pathway in inflammatory bowel disease.
Mitsuyama K; Matsumoto S; Masuda J; Yamasakii H; Kuwaki K; Takedatsu H; Sata M
Anticancer Res; 2007; 27(6A):3749-56. PubMed ID: 17970038
[TBL] [Abstract][Full Text] [Related]
14. IL-6-gp130-STAT3 in T cells directs the development of IL-17+ Th with a minimum effect on that of Treg in the steady state.
Nishihara M; Ogura H; Ueda N; Tsuruoka M; Kitabayashi C; Tsuji F; Aono H; Ishihara K; Huseby E; Betz UA; Murakami M; Hirano T
Int Immunol; 2007 Jun; 19(6):695-702. PubMed ID: 17493959
[TBL] [Abstract][Full Text] [Related]
15. Development of a monoclonal antibody-based enzyme-linked immunoabsorbent assay for the binding of gp130 to the IL-6/IL-6R complex and its competitive inhibition.
Scheller J; Kovaleva M; Rabe B; Eichler J; Kallen KJ; Rose-John S
J Immunol Methods; 2004 Aug; 291(1-2):93-100. PubMed ID: 15345308
[TBL] [Abstract][Full Text] [Related]
16. IL-6 transsignaling: the in vivo consequences.
Jones SA; Richards PJ; Scheller J; Rose-John S
J Interferon Cytokine Res; 2005 May; 25(5):241-53. PubMed ID: 15871661
[TBL] [Abstract][Full Text] [Related]
17. A soluble form of the interleukin-6 family signal transducer gp130 is dimerized via a C-terminal disulfide bridge resulting from alternative mRNA splicing.
Wolf J; Waetzig GH; Reinheimer TM; Scheller J; Rose-John S; Garbers C
Biochem Biophys Res Commun; 2016 Feb; 470(4):870-6. PubMed ID: 26809098
[TBL] [Abstract][Full Text] [Related]
18. Different Soluble Forms of the Interleukin-6 Family Signal Transducer gp130 Fine-tune the Blockade of Interleukin-6 Trans-signaling.
Wolf J; Waetzig GH; Chalaris A; Reinheimer TM; Wege H; Rose-John S; Garbers C
J Biol Chem; 2016 Jul; 291(31):16186-96. PubMed ID: 27226573
[TBL] [Abstract][Full Text] [Related]
19. Comparative activity of Sant7 and anti-IL-6, IL-6R monoclonal antibodies in a murine model of B-cell lymphoma.
Campo S; Serlupi-Crescenzi O; Arseni B; Rossi S; Saggio I; Salone B; Cherubini G; Carminati P; De Santis R
Cytokine; 2005 Sep; 31(5):368-74. PubMed ID: 16061391
[TBL] [Abstract][Full Text] [Related]
20. Promotion of the local differentiation of murine Th17 cells by synovial macrophages during acute inflammatory arthritis.
Egan PJ; van Nieuwenhuijze A; Campbell IK; Wicks IP
Arthritis Rheum; 2008 Dec; 58(12):3720-9. PubMed ID: 19035489
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
